"If you have access to a real-time PCR
instrument, you can use PCR Arrays"
Profiler™ PCR Arrays are the most reliable and sensitive gene
expression profiling technology for analyzing a panel of genes in
signal transduction pathways, biological process or disease related
gene networks. The PCR Arrays can be used for research on cancer,
immunology, stem cells, toxicology, biomarker discovery and validation,
and phenotypic analysis of cells and transgenic animals. See the complete
list of PCR Arrays.
You can use any 96-well or 384-well
real-time PCR instrument. See
instrument-specific setup instructions. Click below for
How it Works
The PCR array is a set of optimized
real-time PCR primer assays on 96-well or
384-well plates for pathway or disease focused genes as well as
quality controls. The PCR array performs gene expression analysis with
sensitivity and the multi-gene profiling capability of a microarray.
your cDNA template with the appropriate ready-to-use PCR master mix,
equal volumes to each well of the same plate, and then run the
cycling program. (Download
||How PCR Arrays Work - Protocol Chart
What it offers?
Performance* - ready-to-use for gene
Time and cost saving
- less than 30 min hands-on
time for analyzing 84 genes
data analysis using our easy-to-use Excel-based
data analysis template or web-based analysis tool
Layout and Controls: The
PCR Arrays are available in both 96- and
384-well plates and are used to monitor the expression of 84 genes
related to a
disease state or pathway plus five housekeeping genes. Controls
are also included on each array for genomic DNA contamination, RNA
general PCR performance
You can easily perform a PCR Array
experiment in your own laboratory, or send
your samples to us and take advantage of our PCR
*: when using complete PCR array
The complete PCR Array System yields a greater-than 85 percent present
as little as 25 ng as much as 5 µg of total RNA from a pathway
genes expressed at a lower level (inflammatory cytokines and
||PCR Arrays Let You See More Genes with
Different amounts of universal total RNA were characterized using the
Human Inflammatory Cytokines and Receptors PCR Array, and the
percentage of detectable genes was calculated for each RNA amount.
As little as 25 ng total RNA yields greater than an 80% positive call,
even for cytokines expressed at very low levels.
The complete PCR Array System demonstrates strong correlations across
replicates, lots, and instruments with average correlation coefficients
0.99 insuring reliable detection of differences in expression between
||PCR Arrays Yield Highly Reproducible
Four replicate sets of raw threshold data (1-4) obtained by two
different scientists (A & B) at two different times (050825
& 060111) on Human Drug Metabolism RT˛ Profiler PCR Arrays are
directly compared. The results demonstrate a high degree of correlation
(R2 > 0.990).
The complete PCR Array System, with high quality input RNA, is
yield single bands of the predicted size without primer dimers or other
secondary products thus providing the most accurate real-time PCR
||PCR Arrays Amplify A Single
Gene-Specific Product in Every Reaction.
Universal total RNA was characterized on the TGFβ / BMP Signaling
Pathway PCR Array, followed by dissociation (melt) curve analysis.
PCR Arrays specifically detect individual genes despite the expression
of related gene family members in the same RNA sample.
To ascertain the oncogenic route that two different human breast tumors
taken, the relative expression level of cancer- and adhesion-related
normal and two different cancerous tissues were compared.
Template cDNAs prepared from total RNA of
normal human breast and two human
breast tumors (BioChain Institute, Inc., 5.0 µg) were characterized in
technical triplicates using the Human Cancer PathwayFinder™ PCR Array
and the Human Extracellular Matrix & Adhesion Molecule PCR
Array with the RT˛ SYBR Green / Fluorescein PCR master mix on the
||ECM & Adhesion PCR Arrays
Revealed Up- and Down-Regulated Genes in Breast Cancer
Total RNA from normal human breast and a human breast tumor were
characterized in technical triplicates, and the relative expression
levels for each gene in the two samples are plotted against each other
in the Scatter Plot.
Genes encoding the matrix metallopeptidases (MMP3 & MMP9) and
their inhibitors (TIMP3) are up-regulated, while genes encoding
integrins (ITGB3 & ITGB4) are down-regulated, by at least
three-fold (outside the silver field) in breast tumors relative to
Rezulin (Troglitazone or "Tro" or "T"), a
PPAR-gamma agonist, was approved for treatment of type 2 diabetes
mellitus, but was
withdrawn from the market due to idiosyncratic liver toxicity. Two
drugs, Avandia (Rosiglitazone or "Rosi" or "R") and Actos (Pioglitazone
or "Pio" or "P"), are considered to be safe treatments for
the same condition. The expression profile of key drug metabolism genes
be different in cells treated with Rezulin versus those treated with
Hepatocellular carcinoma HepG2 cells were
treated at 80% cell confluence with
these three drugs (100 µM, Cayman Chemical) or a DMSO vehicle control
for 24 h.
RNA isolated using the ArrayGrade™ Total RNA Isolation Kit was used to
characterize gene expression with the Human Drug Metabolism and
Stress & Toxicity PathwayFinder™ RT˛ Profiler™ PCR Arrays and
RT˛ SYBR Green / Fluorescein PCR master mix on the Bio-Rad iCycler®.
||Stress & Toxicity
PathwayFinder™ PCR Array Uncovered Idiosyncratic Mechanisms of Action
for Liver Toxicity Caused by 3 PPARγ Agonists.
RNA from HepG2 cells treated with three different glitazone PPARγ
agonists for type 2 diabetes mellitus was characterized, and the
results were compared to that of a vehicle (DMSO) control.
A withdrawn drug with idiosyncratic liver toxicity (Rezulin) induces
very different changes in the expression of stress-related genes than
two safer drugs still on the market (Avandia and Actos).
Back to Top